India is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...

The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

India has a structural advantage in quantum computing. Its size inherently creates challenging optimisation issues, offering a practical te...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

India's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Bio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...